Viewray (VRAY) Stock Rating Upgraded by ValuEngine

Viewray (NASDAQ:VRAY) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday, ValuEngine reports.

VRAY has been the topic of several other reports. Zacks Investment Research upgraded shares of Viewray from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research report on Saturday, February 9th. BidaskClub upgraded shares of Viewray from a “hold” rating to a “buy” rating in a research report on Tuesday, January 22nd. TheStreet downgraded shares of Viewray from a “c-” rating to a “d” rating in a research report on Friday, May 3rd. B. Riley reiterated a “buy” rating and issued a $12.00 price objective (down from $13.75) on shares of Viewray in a research report on Monday, March 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $13.00 price objective on shares of Viewray in a research report on Thursday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $12.63.

Viewray stock opened at $8.25 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.24 and a current ratio of 4.28. Viewray has a 1 year low of $4.86 and a 1 year high of $13.21. The stock has a market capitalization of $790.14 million, a PE ratio of -8.42 and a beta of 1.20.



Viewray (NASDAQ:VRAY) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.12). Viewray had a negative return on equity of 71.16% and a negative net margin of 139.82%. The business had revenue of $20.30 million during the quarter, compared to the consensus estimate of $20.40 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. The company’s quarterly revenue was down 22.5% compared to the same quarter last year. On average, research analysts expect that Viewray will post -0.99 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its stake in Viewray by 2.7% during the 4th quarter. Northern Trust Corp now owns 836,280 shares of the company’s stock valued at $5,077,000 after buying an additional 22,187 shares during the period. BlackRock Inc. increased its stake in Viewray by 51.9% during the 3rd quarter. BlackRock Inc. now owns 4,501,045 shares of the company’s stock valued at $42,130,000 after buying an additional 1,538,108 shares during the period. Essex Investment Management Co. LLC increased its stake in Viewray by 2.9% during the 4th quarter. Essex Investment Management Co. LLC now owns 245,232 shares of the company’s stock valued at $1,489,000 after buying an additional 6,897 shares during the period. Pennsylvania Trust Co increased its stake in Viewray by 31.7% during the 4th quarter. Pennsylvania Trust Co now owns 126,341 shares of the company’s stock valued at $767,000 after buying an additional 30,396 shares during the period. Finally, Prescott Group Capital Management L.L.C. increased its stake in Viewray by 1,141.9% during the 4th quarter. Prescott Group Capital Management L.L.C. now owns 200,476 shares of the company’s stock valued at $1,217,000 after buying an additional 184,333 shares during the period.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

See Also: What is intrinsic value?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.